Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb Zanthoxylum nitidum var. tomentosum

B, Yu; Zhang, Guangping; Jin, Lingling; Zhang, Bo; Dong, Yan; Yang, Hong; Ye, Zuguang; Ma, Tiantian

doi:10.3389/fphar.2017.00489

Cited by 24 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiotensin-converting enzyme inhibitors (ACE-I), insulin-sensitizing agents (including metformin and thiazolidinediones), and hormone-replacement therapy in women can have mild to moderate reduction of PAI-1 levels [ 133 ]. There are direct PAI-1 antagonists known, but none has been cleared for human use yet [ 134 , 135 ].…”

Section: Targeting Thrombosis In Severe Covid-19mentioning

confidence: 99%

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

2020

View full text Add to dashboard Cite

The pathogenesis of Coronavirus disease 2019 (COVID-19) is gradually being comprehended. A high number of thrombotic episodes are reported, along with the mortality benefits of heparin. COVID-19 can be viewed as a prothrombotic disease. We overviewed the available evidence to explore this possibility. We identified various histopathology reports and clinical case series reporting thromboses in COVID-19. Also, multiple coagulation markers support this. COVID-19 can be regarded as a risk factor for thrombosis. Applying the principles of Virchow's triad, we described abnormalities in the vascular endothelium, altered blood flow, and platelet function abnormalities that lead to venous and arterial thromboses in COVID-19. Endothelial dysfunction, activation of the renin-angiotensin-aldosterone system (RAAS) with the release of procoagulant plasminogen activator inhibitor (PAI-1), and hyperimmune response with activated platelets seem to be significant contributors to thrombogenesis in COVID-19. Stratifying risk of COVID-19 thromboses should be based on age, presence of comorbidities, D-dimer, CT scoring, and various blood cell ratios. Isolated heparin therapy may not be sufficient to combat thrombosis in this disease. There is an urgent need to explore newer avenues like activated protein C, PAI-1 antagonists, and tissue plasminogen activators (tPA). These should be augmented with therapies targeting RAAS, antiplatelet drugs, repurposed antiinflammatory, and antirheumatic drugs.

show abstract

Section: Targeting Thrombosis In Severe Covid-19mentioning

confidence: 99%

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

2020

View full text Add to dashboard Cite

show abstract

“…tomentosum and its main compound, toddalolactone, showed PAI-1 inhibitory effects. Toddalolactone suppressed binding of PAI-1 with urokinase-type plasminogen activators (uPA), and therefore attenuated formation of the PAI-1/uPA complex (Yu et al ., 2017). Compounds isolated from Callicarpa nudiflora , including 1,6-di- O -caffeoyl-β-D-glucopyranoside, suppressed platelet aggregation induced by ADP, U45519, and arachidonic acid.…”

Section: Inhibitory Effects Of Medicinal Herbs On Plaque Formationmentioning

confidence: 99%

Medicinal Herbs Effective Against Atherosclerosis: Classification According to Mechanism of Action

Kim

Shim

2019

Biomolecules & Therapeutics

View full text Add to dashboard Cite

Atherosclerosis is a widespread and chronic progressive arterial disease that has been regarded as one of the major causes of death worldwide. It is caused by the deposition of cholesterol, fats, and other substances in the tunica intima which leads to narrowing of the blood vessels, loss of elasticity, and arterial wall thickening, thus causing difficulty in blood flow. Natural products have been used as one of the most important strategies for the treatment and prevention of cardiovascular diseases for a long time. In recent decades, as interests in natural products including medicinal herbs have increased, many studies regarding natural compounds that are effective against atherosclerosis have been conducted. The purpose of this review is to provide a brief over-view of the natural compounds that have been used for the treatment and prevention of atherosclerosis, and their mechanisms of action based on recent research.

show abstract

“…The flowering plant species Toddalia asiatica (L.) Lam. has been found to be efficacious in treating hemostasis, removing blood stasis, and relieving pain [1]. As a traditional medicine that is used in the Guizhou, Guangxi, and Yunnan provinces, the plant is widely applied in the treatment of rheumatic arthralgia, stroke injury, and swelling.…”

Section: Introductionmentioning

confidence: 99%

Development of a rapid UPLC-MS/MS method for the determination of toddalolactone in mouse blood and its application in pharmacokinetics

Zhou

Wang

Caiyun

et al. 2021

AChrom

View full text Add to dashboard Cite

A rapid and simple UPLC-MS/MS method was developed to determine toddalolactone in mouse blood and applied to measure the pharmacokinetics of toddalolactone in mice. Blood samples were first preprocessed by ethyl acetate liquid-liquid extraction. Oxypeucedanin hydrate (internal standard, IS) and toddalolactone were gradient eluted from a UPLC BEH C18 column using a mobile phase consisting of acetonitrile and water (0.1% formic acid). Using electrospray ionization (ESI) as the ionization source, multiple reaction monitoring was used to detect the precursor and product ions of m/z 309.2 and 205.2, respectively, for toddalolactone and of m/z 305.1 and 203.0 for IS, respectively, for quantitative detection. A calibration curve was run over the concentration range of 5–4,000 ng/mL (r > 0.995). The matrix effects ranged from 93.5 to 98.4%, and the recovery was higher than 77.3%. The precision was less than 13%, and the accuracy ranged from 90.9 to 108.4%. The developed UPLC-MS/MS method was successfully used for measuring the pharmacokinetics of toddalolactone in mice after oral (20 mg/kg) and intravenous administration (5 mg/kg), and the absolute bioavailability of toddalolactone was 22.4%.

show abstract

Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb Zanthoxylum nitidum var. tomentosum

Cited by 24 publications

References 39 publications

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

Medicinal Herbs Effective Against Atherosclerosis: Classification According to Mechanism of Action

Development of a rapid UPLC-MS/MS method for the determination of toddalolactone in mouse blood and its application in pharmacokinetics

Contact Info

Product

Resources

About